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Abstract: The pharmacokinetics and immunodynamics of basiliximab were assessed in 37
pediatric de novo liver allograft recipients to rationally design a dose regimen for this age-
group. In part one of the study, patients were given 12 mg/m2 basiliximab by bolus
intravenous injection after organ perfusion and on day 4 after transplant. An interim
pharmacokinetic evaluation supported a fixed-dose approach for part two of the study in
which infants and children received two 10-mg doses of basiliximab and adolescents received
two 20-mg doses. Blood samples were collected over a 12-week period for screening for anti-
idiotype antibodies and analysis of basiliximab and soluble interleukin-2 receptor (IL-2R)
concentrations. Basiliximab clearance in infants and children , 9 yr of age (n530) was
reduced by< 50% compared with adults from a previous study and was independent of age to
9 yr, weight to 30 kg, and body surface area to 1.0 m2. Clearance in children and adolescents
9–14 yr of age (n57) approached or reached adult values. An average of 15% of the dose was
eliminated via drained ascites fluid, and drug clearance via this route averaged 29% of total
body clearance. Patients with .5 L of ascites fluid drainage tended to have lower systemic
exposure to basiliximab. CD25-saturating basiliximab concentrations were maintained for
2769 days in part one of the study (mg/m2 dosing) with infants exhibiting the lowest
durations. CD25 saturation lasted 37611 days in part two of the study, based on the fixed-
dose regimen (p5 0.004 vs. mg/mg2 dosing), but did not show the age-related bias observed in
part one of the study. Anti-idiotype antibodies were detected in four patients, but this did not
influence the clearance of basiliximab or duration of CD25 saturation. All 40 enrolled patients
were included in the intent-to-treat clinical analysis. Episodes of acute rejection occurred in 22
patients (55%) during the first 12 months post-transplant. Three patients experienced loss of
their graft as a result of technical complications, and six patients died during the 12-month
study. Basiliximab was well tolerated by intravenous bolus injection, with no cytokine-release
syndrome or other infusion-related adverse events. Hence, basiliximab was safe and well
tolerated in pediatric patients undergoing orthotopic liver transplantation. To achieve similar
basiliximab exposure as is efficacious in adults, pediatric patients , 35 kg in weight should
receive two 10-mg doses and thosei 35 kg should receive two 20-mg doses of basiliximab by
intravenous infusion or bolus injection. The first dose should be given within 6 h after organ
perfusion and the second on day 4 after transplantation. A supplemental dose may be
considered for patients with a large volume of drained ascites fluid relative to body size.
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Basiliximab is a high-affinity chimeric monoclo-
nal antibody directed to the interleukin-2 receptor
on activated T lymphocytes (IL-2R or CD25) and
which is used to prevent acute cellular rejection in
organ transplantation. A multi-center clinical trial
has established the efficacy of basiliximab in adult
liver transplantation (1). Basiliximab is applied in
this indication in a two-dose regimen in the first
4 days after transplantation and provides CD25
saturation for an average of 4–6 weeks (2).
It is a reasonable premise that pediatric liver
allograft recipients would also benefit from this
agent. To assess this under controlled conditions,
a multi-center, open-label study was performed to
gain clinical experience with basiliximab in this
Abbreviations: AUC, area under the concentration–time curve;
CD25, cluster of differentiation for IL-2 receptor, a-chain; CL, total
body clearance; CLasc, clearance via ascites fluid drainage; Cmax.,
maximum concentration; CMV, cytomegalovirus; CsA, cyclosporin
A; ELISA, enzyme-linked immunosorbent assay; IL-2R, interleu-
kin-2 receptor; sIL-2R, soluble IL-2 receptor; tK, half-life; Vc,
central distribution volume; Vss, steady-state distribution volume.
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population of patients while gathering pharma-
cokinetic and pharmacodynamic data to ration-
ally develop a dosing algorithm across this
age-group. This article presents the pharmacoki-
netic and pharmacodynamic aspects of the study
with a summary of the main clinical findings.
The specific objectives were as follows:
1 To characterize the pharmacokinetics of
basiliximab in pediatric de novo liver allograft
recipients and explore for demographic covariates
such as age, weight, and body surface area.
2 To characterize the pharmacodynamics of
basiliximab by serial soluble IL-2R measurements
in serum.
3 To screen for anti-idiotype antibody
responses.
4 To use the composite of the above evalua-
tions to derive a dosing algorithm for the rational
use of basiliximab in pediatric liver transplant
patients.
5 To assess the safety, tolerability, and pre-
liminary efficacy of basiliximab, in combination
with CsA microemulsion (Neoral1, Novartis
Pharmaceuticals, Basel, Switzerland) and corti-




This multi-center, open-label study enrolled 40 pediatric de novo liver
transplant patients. Boys and girls under 16 yr of age undergoing a
first liver transplant from a cadaveric or living donor were eligible.
Patients with fulminant hepatic failure, hemodynamic instability
requiring pressor and/or inotropic support, primary non-function of
the allograft, or graft thrombosis requiring re-operation or re-
transplantation, were excluded. Basiliximab was added to a baseline
CsA/corticosteroid immunosuppressive regimen. Target CsA trough
levels were 150–500 ng/mL in month 1 and 150–300 ng/mL there-
after.
The study was divided into two parts. In part one, 20 patients were
enrolled and received a basiliximab regimen scaled down from the
adult dose according to body surface area. An interim pharmaco-
kinetic evaluation was then performed to design a rational dose
regimen to be prospectively evaluated. In part two of the study, 20
patients were enrolled and received a stepwise fixed-dose regimen
with a weight transition point as described below. Patients in both
parts of the study were followed-up for 12 months to assess the safety
and tolerability of basiliximab in this population of patients and to
evaluate acute rejection episodes and graft and patient survival at 6
and 12 months post-transplantation. The Institutional Review Board
or Research Ethics Committee at each participating institution
approved the protocol, and each patient’s parent or guardian gave
written, informed consent.
Drug formulation and dosing
Basiliximab (Simulect1, Novartis Pharmaceuticals) was supplied as
a lyophilizate of 10-mg strength. Immediately prior to administra-
tion, lyophilizates were reconstituted in 2.5 mL of sterile water for
injection. In part one of the study, a body surface area-adjusted
dosing approach was applied. Patients were administered two doses
of basiliximab, 12 mg/m2 (not to exceed 20 mg), each. In part two of
the study, patients who weighed ,40 kg received two doses of 10 mg
and those who weighed i 40 kg received two doses of 20 mg. Doses
were administered by bolus intravenous injection in < 10 s. The first
dose was injected within 8 h after organ perfusion on day 0; the
second dose was administered 4 days after transplant surgery.
Basiliximab was given in addition to CsA microemulsion and a
standard corticosteroid taper.
Pharmacokinetic sampling
Eighteen 1-mL venous blood samples were obtained over a 12-week
period after transplantation. Specifically, samples were drawn before
and 30 min after each dose of basiliximab (on days 0 and 4), daily
through day 7, and then in weeks 2, 3, 4, 5, 6, 8, 10, and 12. Blood
samples were drawn into collection tubes without anti-coagulants
and allowed to clot at ambient temperature. Serum was harvested
within 2–3 h of blood collection and frozen at –188C at the local
laboratory until shipment to the central analytical site. Total volumes
of drained ascites fluid were recorded daily while the drain was in
place to a maximum of day 14. A 5-mL sample of each daily total
volume was centrifuged, following which 3 mL of the supernatant
was transferred to a plastic tube and frozen at –188C.
Basiliximab serum concentrations
Basiliximab concentrations were measured in serum and ascites fluid
with a validated idiotype-specific two-step competitive ELISA
method using a fluorescein-labeled polyclonal rabbit anti-idiotype
antibody and biotinylated basiliximab, as previously described (3).
Assay accuracy (% deviation from the nominal concentration) for
quality control samples ranged from –2.6% to 0.6% and assay
precision ranged from 5.0 to 6.8%. The quantification limit was
0.06 mg/mL for both serum and ascites fluid.
SIL-2R concentrations
sIL-2R serum concentrations were measured using a commercially
available ELISA kit (Boehringer Mannheim Biochemie, Mannheim,
Germany). Because basiliximab complexes with sIL-2R rendering it
undetectable by the probe monoclonal antibodies in the kit, serum
samples were pretreated by 1 : 20 dilution in assay buffer and addition
of 25 mg/mL anti-idiotype antibody to dissociate the basiliximab–
sIL-2R complex, which allowed detection of sIL-2R. Following this
step, the assay was then performed according to the manufacturer’s
instructions. Assay accuracy for quality control samples ranged from
–0.7 to 1.4% and precision ranged from 6.7 to 9.3%. The
quantification limit was 11 ng/mL.
Anti-idiotype antibody screening
Serum samples from baseline and week 12 were screened for anti-
idiotype antibodies with a validated competitive ELISA method in
which a fixed amount of fluorescein-labeled rabbit anti-idiotype
antibody and the human anti-idiotype antibody possibly present in
the sample compete for binding with a fixed amount of biotinylated
basiliximab. The quantification limit was 0.3 mg/mL.
Pharmacokinetic evaluation
A standard two-compartment pharmacokinetic model was fitted to
the basiliximab concentration–time data to derive the following
pharmacokinetic parameters: Cmax. after the first bolus injection,
cumulative AUC, CL, Vc and Vss, and elimination tK. The CLasc
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was calculated as the quotient of the total amount of basiliximab
eliminated via this route divided by the correspondingAUC in serum.
Duration of CD25 saturation
The duration of CD25 saturation was estimated by two metrics. The
pharmacokinetic metric was the duration post-transplant over which
serum basiliximab concentrations exceeding 0.1 mg/mL (the in vivo
threshold saturating concentration determined in adult patients) (3).
The sIL-2R metric was taken from the sIL-2R profiles as the time
post-transplant when the sIL-2R concentration decreased by i 10%
from the plateau phase maximum.
Safety and efficacy
Safety and tolerability were evaluated by recording laboratory
variables, physical examinations, and vital signs, and by the
incidence of adverse events (particularly those related to immuno-
suppression such as viral, fungal or opportunistic infections and
malignant neoplasms), serious adverse events and infections.
Efficacy was evaluated by recording the incidence of acute rejection
episodes within 12 months after transplantation and actual patient
and graft survival at 12 months after transplantation. An acute
rejection was defined to have occurred if the rejection episode was
biopsy confirmed and anti-rejection treatment administered.
Results
Demographics
Forty patients were enrolled in the study. Two
patients did not receive the second dose and one
did not receive any basiliximab. The 37 patients
evaluable for pharmacokinetics were 15 boys and
22 girls categorized as 20 infants (,2 yr), 15
children (2–11 yr), and two adolescents
(12–14 yr). They ranged in age from 2 months
to 14 yr, in weight from 4 to 44 kg, and in body
surface area from 0.23 to 1.38 m2. There were 30
whites, three blacks, and four of other ethnicities.
The majority of patients (n533) received an organ
from a cadaveric donor.
Study course and dosing strategies
Eighteen evaluable patients were enrolled in part
one of the study and received the adult dose scaled
down by body surface area: namely, 12 mg/m2 on
days 0 and 4. This corresponded to 7.764.2 mg/
dose (range: 3.6–17.0 mg). The protocol-sched-
uled interim pharmacokinetic evaluation indi-
cated that basiliximab clearance in infants and
children was reduced compared with adults but
independent of age, weight, and body surface
area. Clearance in adolescents began to take on or
reach adult values. On this basis, a stepwise, fixed-
dose regimen with a weight transition point was
selected for part two of the study. Specifically,
infants and children received two 10-mg doses and
adolescents received two 20-mg doses (the stan-
dard adult regimen). The 40-kg transition point
between the two dosage regimens was chosen
based on data available at the interim evaluation.
Part two of the study enrolled 19 evaluable
patients.
Pharmacokinetics
The average Cmax. in part two of the study (fixed-
dose regimen) was 5.661.4 mg/mL (range,
3.4–9.0) and did not differ significantly from
study part one (mg/m2 dosing): 6.161.9 mg/mL
(range, 3.5–9.7), p 5 0.44. Likewise, AUC values
were similar with the two dosing approaches:
34613 mg.day/mL in part one and 35612 mg.day/
mL in part two (p 5 0.74). As clearance,
distribution volume, and tK are dose-independent
parameters, these data were pooled across all
patients from the total study population (n537)
to examine their relationship to demographic
characteristics.
Demographic covariates
The relationships of clearance vs. age and weight
are shown in Fig. 1. The relationship to body
surface area was similar to that of weight (data not
shown). The plots indicated that for infants and
children, clearance was independent of age (up to
9 yr) and weight (up to < 30 kg). This was
confirmed by linear regression analysis inasmuch
as the slopes of the regression lines through these
data were not significantly different from zero:
0.468 mL/h/yr (p 5 0.38) and 0.414 mL/h/kg
(p5 0.06). Clearance in older children and ado-
lescents 9–14 yr was transitional, with values
starting to take on or reach adult values. These
findings in the full population confirmed the
clearance–demographic relationships character-
ized at the interim evaluation, as mentioned
above. Clearance and other pharmacokinetic
parameters are summarized in Table 1 and
compared with adult values.
The Vc increased with age, weight, and body
surface area over the full population range, as
indicated by regression analyses showing signifi-











CL (mL/h) 19.366.5 46.6619.3 55.0626.2
Vc (L) 2.060.9 4.061.3 5.760.9
Vss (L) 4.163.9 6.462.4 9.764.2
tK (days) 7.664.6 5.862.5 8.766.7
CL, clearance; tK, half-life; Vc, central distribution volume; Vss, steady-state
distribution volume.
Adult data were obtained from ref. 2.
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cant, positive slopes (p,0.001). The Vss was
independent of age and body size. Both volume
terms began to reach adult values in adolescence.
The clinical impact of the dependence of Vc on
body size applies mostly to the peak concentration
whereby higher peaks would be expected in
young, small patients when receiving the fixed-
dose regimen. This, however, was not the case (as
noted above) as the Cmax. was similar among
patients who received body surface area-based
and fixed dosing. This was because the slopes of
the relationships between Vc and age (0.19 L/yr),
weight (0.07 L/kg), and body surface area (2.35 L/
m2) were very shallow. The elimination tK showed
no dependence on age, weight, or body surface
area among pediatric patients. Pediatric tK values
were similar to those of adults, as shown in
Table 1.
Ascites fluid drainage
Ascites fluid drains were in place for a median of
9 days (range: 3–36 days). Eight patients retained
their drain beyond day 14 (range: 15–36 days).
The median cumulative volume of drained fluid
over the first 2 weeks after transplantation was
1.3 L (range: 0.2–28.8 L). Cumulative drainages
of j 5 L had no discernible influence on the total
body clearance of basiliximab, whereas patients
with .5 L of drainage (n55) had generally higher
total body clearances (median, 41.1 mL/h; range:
25.7–82.1 mL/h).
Ascites fluid samples for bioanalysis were
received from 35 patients. With few exceptions,
basiliximab was quantifiable in all samples. The
median cumulative amount of basiliximab elimi-
nated via drained fluid was 2.86 mg (range:
0.34–19.05 mg). This represented a median of
15.1% (range: 1.7–67.1%) of the total basiliximab
dose administered. While the drain was in place,
the median clearance via this route was 6.0 mL/h
(range: 0.7–50.1 mL/h) which represented, on
average, 28.5% (range: 4.9–96.0%) of the total
body clearance.
SIL-2R profiles
Figure 2 shows a representative plot demonstrat-
ing the relationship between basiliximab pharma-
cokinetics and the time course of sIL-2R levels.
sIL-2R measurements were performed in all
patients (n518) in part one of the study. Before
transplantation, sIL-2R concentrations were gen-
erally below or at the assay quantification limit
(11 ng/mL). Inspection of the individual plots
revealed a temporal pattern, whereby concentra-
tions rose over the first 2–3 weeks after trans-
plantation and then entered a plateau phase.
Concentrations on day 4 prior to the second dose
were 119662 ng/mL and the average Cmax.
plateau was 198673 ng/mL. After serum basilix-
imab concentrations reached the CD25 saturation
threshold of 0.1 mg/mL, sIL-2R concentrations
began a precipitous decline, returning to baseline
levels within 1–2 weeks, as demonstrated in
Fig. 2. As blood samples for sIL-2R measurement
were taken at weekly or bi-weekly intervals, a
precise estimate of the number of days of CD25
saturation could not be derived with this metric.
However, the time interval during which the
decline from the plateau phase began was used as
an estimate of the onset of CD25 de-saturation.
This sIL-2R-guided estimate either included (44%
of profiles) or was within a median of 1 week (56%
of profiles) of the day on which serum basiliximab
concentrations fell below 0.1 mg/mL. Hence, this
biomarker provided independent support for the
pharmacokinetic estimate of the duration of
CD25 saturation. The latter, as described below,
was the primary metric for estimating the dura-
tion of receptor saturation.
Duration of CD25 saturation
Serum basiliximab concentrations on day 4 prior
to administration of the second dose were 0.960.5
mg/mL (range: 0.3–1.8). Regardless of the dosing
Fig. 1. Relationship between basiliximab clearance vs. age
in pediatric patients in the upper panel and vs. weight in
pediatric (filled triangle) and adult (open triangle) patients in
the lower panel.
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approach, CD25-saturating concentrations were
maintained throughout the inter-dose interval.
The overall duration of CD25-saturating concen-
trations in part one of the study was 2769 days
(range: 13–46) with the lowest values among
infants and young children, as shown in the upper
panel of Fig. 3. With the fixed-dose approach of
part two of the study, CD25 saturation lasted
37611 days (range: 21–62 days; p50.004), and
did not exhibit an age-related bias. Figure 3 also
demonstrates that the CD25 saturation durations
from part two of the study conformed to the adult
distribution, with the majority falling within adult
quartiles 2 through 4.
The enhanced clearance of basiliximab in
patients with pronounced ascites fluid loss also
had an impact on the duration of CD25 satura-
tion, as shown in the lower panel of Fig. 3. As
noted above for clearance, patients with ascites
fluid drainage in excess of 5 L in the first post-
transplant week tended to have CD25 saturation
duration in the lower adult distribution quartiles.
Anti-idiotype antibody responses
Of the 39 patients enrolled who received one or
both basiliximab doses, three had no serum
samples available after transplantation that were
free of quantifiable basiliximab and therefore
these samples could not be screened as a result of
potential assay interference. Of the remaining 36
patients, four (11%) had detectable anti-idiotype
antibody ranging from 0.5 to 1.7 mg/mL. Despite
the presence of anti-idiotype antibody, the
clearance of basiliximab (range: 13–26 mL/h)
and the duration of CD25 saturation (range:
23–62 days) did not appear to be affected.
Refinement of the pediatric dosing algorithm
The appropriateness of the 40-kg weight tran-
sition point used in part two of the study could not
be examined in detail as few older children and
adolescents around this weight point were
enrolled. Data from a similar study in pediatric
kidney allograft patients (4) were combined, as
shown in Fig. 4. A weight transition point of
35 kg, as used in renal transplantation (4), also
conformed to the clearance-weight pattern from
pediatric liver transplantation. With the com-
bined data set, selection of 35 kg for transferring
between the two pediatric dose regimens appeared
to be more appropriate than 40 kg.
Clinical findings
The combined sample of patients from both parts
of the study were separated into two age cohorts
Fig. 2. Pharmacokinetic-dynamic profile from a represent-
ative pediatric patient showing the time courses of basiliximab
concentrations (filled circle) and soluble interleukin-2 recep-
tor (IL-2R) levels (open square).
Fig. 3. Duration of CD25 saturation vs. age (upper panel)
anddrained ascites fluidvolume (lower panel) from part oneof
the study with mg/m2 dosing (open circle) and from part two of
the study with fixed dosing (filled circle). Gridlines identify the
distribution quartiles (Q) from adults.
Fig. 4. Comparison of the clearance-weight relationships of




(,3 yr and 3–15 yr) for analyses of clinical
outcomes. Acute rejection occurred in 55% of
patients and was slightly higher (60%) for 3–15-yr-
old patients than for those ,3 yr of age (52%).
The incidence of rejection was higher than in
studies of basiliximab in adult liver transplant
patients, but is similar to the incidence reported
for other immunosuppressive regimens in pedia-
tric patients (5–7). Approximately half of these
rejections occurred while CD25 was saturated
with the remaining half occurring after de-
saturation. The duration of CD25 saturation in
patients with a rejection episode was similar to
that of patients who remained rejection free.
Three patients (7.5%) experienced loss of their
first graft as a result of technical complications,
and six patients (15%) died during the study.
All patients experienced adverse events, the
incidence and distribution of which conformed to
the expected profile of liver transplant recipients.
The most common adverse events were hyperten-
sion (70%), fever (50%), and diarrhea (50%); 25%
of adverse events were considered to be related to
the study medication. One patient developed
malignancy (post-transplant lymphoproliferative
disorder in month 9 post-transplant). Infections
were experienced by 36 patients (90%). Most
reported infections for which an organism was
identified were bacterial (58% of patients) or viral
(35% of patients). The most frequently reported
manifestation of infection was sepsis (30% of
patients). The protocol recommended CMV
prophylaxis with the final decision left to the
clinician. CMV infections were reported in 10
patients (25%). Basiliximab was well tolerated by
intravenous bolus injection, without evidence of
cytokine-release syndrome, acute hypersensitivity
or other infusion-related adverse events. There
were six deaths, all of which occurred in patients
,3 yr of age, and none were caused by rejection.
Discussion
This multi-center study has gathered extensive
pharmacokinetic data, along with tolerability and
safety information, on the use of basiliximab
in pediatric de novo liver transplant patients.
Importantly, the population was well distributed
over the full demographic ranges for age
(2 months to 14 yr), weight (4–44 kg), and body
surface area (0.23–1.38 m2), which are represen-
tative of those in the general pediatric liver
transplant population. The two-part study
design and the data it generated provide support
for a rational dosing algorithm for pediatric liver
allograft recipients.
Part one of the study, using a mg/m2 dosing
regimen scaled down from that employed in adult
liver transplantation, indicated that basiliximab
clearance in infants and young children was
relatively independent of the common demo-
graphic variables conventionally employed in
pediatric dosing, namely: age, weight, and body
surface area. On average, clearance in this age-
range was reduced by < 50% compared with
adults. On this basis, a fixed-dose approach was
applied in part two of the study, whereby infants
and children received one-half of the standard
adult dose, specifically, two 10-mg doses.
Clearances in older children and adolescents
were either intermediate between values in
younger children and adults or were similar to
adult values. On this basis, they received the
standard adult dose of two 20-mg doses in part
two of the study. The transition point between the
two regimens was based on weight, with 40 kg
appearing to separate the two populations
adequately, based on data from part one of the
study.
It was the intention in part two of the study to
provide confirmation of these clearance–demo-
graphic relationships in a greater number of
patients, as well as to focus additional attention
on the transition point between childhood and
adolescence, which was sparsely represented in
part one. The complete study results (from a total
of 30 infants and children ranging in age from
2 months to 9 yr) fully supported the clearance–
demographic relationship described above, from
part one of the study, that clearance is indepen-
dent of common demographic covariates. At the
transition between childhood and adolescence
(10–14 yr) there were, however, only five patients
in the full study population. These data alone did
not allow a specific weight cut-off to be specified
for transferring between the two regimens. When
these data in liver-transplanted pediatric patients
were supplemented with those from a similar
study in pediatric kidney transplantation (4), they
were in agreement with the approach taken in the
latter transplant indication to use 35 kg as the
weight transition point, as shown in Fig. 4.
Loss of basiliximab in ascites fluid drainage was
demonstrable in all patients in this study and
agrees with similar observations in adult liver
allograft recipients (3). Because duration of
ascites drainage and cumulative volume are
highly patient-specific, this route of drug elimina-
tion can inflate the overall pharmacokinetic
variability in CL and distribution volume across
the population. When cumulative volumes were
j 5 L (which is usually the case in uncomplicated
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post-transplant courses) there was no major
impact on overall clearance. Total volumes in
excess of 5 L tended to be associated with higher
total body clearances and a shorter duration of
CD25 saturation. Combining these data with the
experience in adult liver transplantation (2)
suggested that a supplemental dose in these
cases may be considered on a case-by-case basis.
The patterns noted for drug clearance were
paralleled by similar patterns in the duration of
CD25 saturation. In part one of the study, when
dosing was based on body surface area, infants
and very young children had the shortest duration
of saturation compared with the remainder of the
pediatric population and with the adult distribu-
tion of values. This was a direct consequence of
the fact that infants and very young children had
the same drug clearance as older children but
received lower milligram doses because of a
smaller body size. With the fixed-dose regimen
in part two of the study, the pattern was improved
for this age cohort, as shown with the filled
symbols in Fig. 3. Moreover, the distribution of
duration of CD25 saturation was more uniform
across the full pediatric demographic range and
better centered on that achieved in adults.
Basiliximab had a low potential for immuno-
genicity in this pediatric population. Four
patients had anti-idiotype antibody responses.
Nonetheless, these did not appear to be neutraliz-
ing antibodies inasmuch as the basiliximab
clearances and duration of CD25 saturation in
these patients were similar to values in the
remainder of the study population.
The three main pharmacokinetic conclusions
from this study which support a rational basilix-
imab dosing algorithm for pediatric de novo liver
transplantation were:
1 Basiliximab clearance in infants and children
was reduced by < 50% compared with adults but
was independent of age, weight, and body surface
area. Clearance among adolescents was similar to
that of adults.
2 Body surface area-adjusted dosing yielded a
shorter duration of CD25 saturation in infants
and very young children compared with older
pediatric patients and adults. The fixed-dose
approach used in part two of the study resolved
this problem
3 Loss of basiliximab in drained ascites fluid
contributed to a higher CL and shorter duration
of CD25 saturation, especially when the total
drained volume exceeded < 5 L in the first week
after transplantation.
On the basis of these data and those from a
similar study in pediatric kidney transplantation
(4), a fixed dose of 10 mg administered within 6 h
after organ perfusion and again on day 4 after
transplantation is recommended for pediatric
patients who weigh,35 kg. For pediatric patients
who weigh i 35 kg, the standard adult dose is
recommended, namely, two 20-mg doses. An
additional dose of 10 or 20 mg, respectively, on
day 7 may be considered on a case-by-case basis,
depending on the volume of ascites fluid drained
relative to the patient’s body size. Our data
indicate that a drainage of .5 L in the first week
after transplantation should alert the clinician to
consider an additional dose.
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